As part of a wave of good news for the beleaguered Hospira, the company said it will inject $120m into its McPherson, Kansas, facility, which will result in 150 new jobs over the next five years.
Manufacturing powerhouse Roche is doubling down on its small molecule manufacturing with investments of $134.6m in two facilities in Basel, Switzerland.
Pharmaceutical clients view contract research organisations (CROs) with private equity investments as unstable and more focused on financial growth than their operations, according to Italian CRO Cromsource.
Molecular Profiles has invested in hot melt extrusion (HME) and nano milling capabilities citing client demand for improving the bioavailablity of drugs.
Ireland remains a significant small molecule drug manufacturing hub the Industrial Development Agency (IDA) says, despite a number of API plant closures.
Aurobindo says it can make the loss making European generics operations it is buying from Actavis profitable by combining them with its production network in India.
The higher demand for preclinical toxicity testing reported by public CROs last year may also be being seen by private firms if recent investments are any indication.
Eli Lilly is investing over $700m (€518m) at a number of its insulin producing sites globally saying it is a response to the “growing diabetes epidemic.”
US contractor SAFC has joined the growing list of drugmakers and CMOs to invest in ADCs by announcing plans to add commercial-scale production capacity.
Vetter says plans for a $100m (€74m) expansion are driven by continued growth in the biopharma industry and keep the firm one step “ahead of the curve.”
Investing in antibody-drug conjugates (ADCs) made sense despite CMO competition and the fact few of these hybrid drugs have been approved to date says Carbogen Amcis CEO, Mark Griffiths.
Mylan announced on Tuesday that it received approval from Indian regulators to acquire Agila for $1.6B just as a recent report from India’s Parliament criticizes foreign companies’ increasing control of the industry in the country.
Private equity firm KKR announced today it will acquire RPS (ReSearch Pharmaceutical Services) from Warburg Pincus and will merge the company with PRA International.
After patent expiration led to facility shuttering and cutbacks, Irish manufacturing will receive a $130m (€100m) boost to prepare for Pfizer’s new pipeline, the company says.
Sponsors are piling on more responsibilities for their CRO partners, but the question of how that will translate into increases in risk and profit sharing is a point of contention.
Boehringer Ingelheim will build a biomanufacturing facility in Shanghai in a strategic alliance designed to cater for Pharmas nervous about setting up plants in China.
Private equity firm Water Street has invested an undisclosed sum in clinical trial services group CCBR-Synarc citing opportunities in the patient recruitment and image analysis markets as the key driver for the move.
The US FDA has completed its re-inspection of Hospira’s Rocky Mount, North Carolina, plant and cited the company with 20 violations, three of which were repeat observations, according to an SEC filing.
Teva says the offloading of its Californian manufacturing facility is part of cost-cutting plans designed to save $2bn (€1.5bn). in the next few years.
CROs invest in scope and scale while private-equity groups buy firms they can expand according to Fairmount Partners’ managing director, Neal McCarthy.
Cambridge Major Labs’ (CML) new private-equity investor plans to expand the CMO’s chemistry and API business and assess cross selling synergies with other firms in its portfolio.
Novasep has joined the growing number of manufacturers betting on the antibody drug conjugate (ADC) market with a €3m investment at its plant in Le Mans, France.
No job losses, facility divestitures or strategic changes are planned at DPT Laboratories according to new owner Renaissance Pharma, which bought the CDMO in an out-of-the-blue deal last week.
